Published in
Taylor and Francis Group, Journal of Medical Economics (JME), p. 1-61, 2023
DOI: 10.1080/13696998.2023.2293379
Links
Tools
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
Journal article published in 2023 by
T. Spelman 
,
Wl L. Herring ,
C. Acosta ,
R. Hyde,
Vg G. Jokubaitis ,
E. Pucci,
A. Lugaresi ,
G. Laureys,
Ek K. Havrdova,
D. Horakova,
G. Izquierdo,
S. Eichau,
S. Ozakbas,
R. Alroughani,
T. Kalincik
and other authors.
,
Wl L. Herring ,
C. Acosta ,
R. Hyde,
Vg G. Jokubaitis ,
E. Pucci,
A. Lugaresi ,
G. Laureys,
Ek K. Havrdova,
D. Horakova,
G. Izquierdo,
S. Eichau,
S. Ozakbas,
R. Alroughani,
T. Kalincik
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 